Alder's Antibody Selection (ABS) Process
Alder has developed a unique antibody identification process that is able to identify very potent and rare therapeutic antibodies. The process enables rapid discovery directly from an immunized host using proprietary biological techniques. Unlike existing technologies, Alder’s ABS process has the ability to assess function directly at the outset while allowing broad epitope coverage. 
- Proven operational in a variety of hosts
- Fully exploits the immune system repertoire
- Supports extensive epitope coverage and diversity
- Pairs functional activity with antibody identification
Alder's ABS process allows for the unique generation of multiple high-quality, function-modifying antibodies. This improves speed and efficiency in the discovery process, creating great flexibility that allows Big Pharma and biotech companies to take numerous high-quality candidates into the clinic.
Paired with Alder’s Mab Xpress yeast expression technology, Alder’s ABS process accelerates the progression of antibodies into in vivo studies. In fact, the timeline from antigen to bulk product has been shown to be approximately 1.5 years, or approximately two years faster than typical mammalian processes.
ABS Timeline for Human Therapeutic Generation
